[
  {
    "source": "Upadacitinib",
    "target": "Inflammatory Bowel Disease",
    "relationship": "treats",
    "description": "Upadacitinib is used for treating inflammatory bowel disease (IBD) in patients who inadequately respond to anti-TNF-α therapies."
  },
  {
    "source": "Risankizumab",
    "target": "Inflammatory Bowel Disease",
    "relationship": "treats",
    "description": "Risankizumab is used for treating inflammatory bowel disease (IBD) in patients who inadequately respond to anti-TNF-α therapies."
  },
  {
    "source": "Upadacitinib",
    "target": "Crohn's Disease",
    "relationship": "treats",
    "description": "Upadacitinib is associated with the clinical response in Crohn's disease patients who are anti-TNF-α inadequate responders."
  },
  {
    "source": "Risankizumab",
    "target": "Crohn's Disease",
    "relationship": "treats",
    "description": "Risankizumab is associated with the clinical response in Crohn's disease patients who are anti-TNF-α inadequate responders."
  }
]